WCM Investment Management LLC Has $439.14 Million Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

WCM Investment Management LLC lessened its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 27.0% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 714,722 shares of the medical research company's stock after selling 264,735 shares during the period. WCM Investment Management LLC owned approximately 0.19% of Thermo Fisher Scientific worth $439,140,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of TMO. Vanguard Group Inc. raised its stake in Thermo Fisher Scientific by 0.4% during the first quarter. Vanguard Group Inc. now owns 33,095,791 shares of the medical research company's stock worth $19,235,605,000 after acquiring an additional 117,353 shares in the last quarter. Capital World Investors lifted its holdings in Thermo Fisher Scientific by 10.0% during the 1st quarter. Capital World Investors now owns 13,493,852 shares of the medical research company's stock valued at $7,842,762,000 after purchasing an additional 1,231,059 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in Thermo Fisher Scientific by 1.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 10,054,621 shares of the medical research company's stock valued at $5,843,848,000 after buying an additional 156,675 shares in the last quarter. Capital Research Global Investors increased its holdings in shares of Thermo Fisher Scientific by 1.5% during the first quarter. Capital Research Global Investors now owns 8,113,137 shares of the medical research company's stock worth $4,715,436,000 after buying an additional 123,523 shares in the last quarter. Finally, Ameriprise Financial Inc. raised its stake in shares of Thermo Fisher Scientific by 32.2% in the second quarter. Ameriprise Financial Inc. now owns 2,481,257 shares of the medical research company's stock valued at $1,372,157,000 after acquiring an additional 604,895 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have issued reports on TMO shares. Stephens initiated coverage on Thermo Fisher Scientific in a research report on Tuesday, October 1st. They issued an "overweight" rating and a $680.00 price objective for the company. Bernstein Bank increased their price objective on shares of Thermo Fisher Scientific from $565.00 to $625.00 and gave the stock a "market perform" rating in a report on Tuesday, October 22nd. Morgan Stanley upped their target price on shares of Thermo Fisher Scientific from $655.00 to $680.00 and gave the stock an "overweight" rating in a research report on Friday, September 20th. Barclays lowered their price target on shares of Thermo Fisher Scientific from $620.00 to $610.00 and set an "equal weight" rating for the company in a report on Wednesday, October 23rd. Finally, Evercore ISI lowered their target price on Thermo Fisher Scientific from $630.00 to $620.00 and set an "outperform" rating for the company in a research note on Thursday, October 24th. Four analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $649.33.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $558.12, for a total value of $5,581,200.00. Following the sale, the chief executive officer now directly owns 33,608 shares of the company's stock, valued at approximately $18,757,296.96. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, SVP Michael A. Boxer sold 2,000 shares of the business's stock in a transaction that occurred on Friday, October 25th. The shares were sold at an average price of $560.16, for a total value of $1,120,320.00. Following the completion of the transaction, the senior vice president now directly owns 12,736 shares in the company, valued at approximately $7,134,197.76. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $558.12, for a total transaction of $5,581,200.00. Following the sale, the chief executive officer now owns 33,608 shares in the company, valued at $18,757,296.96. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 28,150 shares of company stock worth $15,676,125 over the last ninety days. 0.34% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Stock Down 0.9 %

TMO stock traded down $4.82 during mid-day trading on Monday, hitting $546.92. 1,317,448 shares of the company were exchanged, compared to its average volume of 1,461,565. The firm has a market cap of $209.20 billion, a P/E ratio of 34.59, a P/E/G ratio of 3.65 and a beta of 0.79. Thermo Fisher Scientific Inc. has a 1-year low of $439.11 and a 1-year high of $627.88. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63. The firm's 50 day simple moving average is $593.95 and its 200 day simple moving average is $583.73.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, topping analysts' consensus estimates of $5.25 by $0.03. The firm had revenue of $10.60 billion during the quarter, compared to analyst estimates of $10.63 billion. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The company's revenue for the quarter was up .2% compared to the same quarter last year. During the same period in the prior year, the business earned $5.69 EPS. On average, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 21.69 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 15th. Stockholders of record on Friday, December 13th will be issued a $0.39 dividend. This represents a $1.56 annualized dividend and a dividend yield of 0.29%. The ex-dividend date is Friday, December 13th. Thermo Fisher Scientific's payout ratio is 9.78%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.